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Abstract
PTEN hamartoma tumour syndrome is a diverse multi-system disorder predisposing to the development of hamartomatous
growths, increasing risk of breast, thyroid, renal cancer, and possibly increasing risk of endometrial cancer, colorectal cancer
and melanoma. There is no international consensus on cancer surveillance in PHTS and all current guidelines are based on
expert opinion. A comprehensive literature review was undertaken and guidelines were developed by clinicians with
expertise from clinical genetics, gynaecology, endocrinology, dermatology, radiology, gastroenterology and general surgery,
together with affected individuals and their representatives. Recommendations were put forward for surveillance for breast,
thyroid and renal cancers. Limited recommendations were developed for other sites including endometrial, colon and skin.
The proposed cancer surveillance recommendations for PHTS require a coordinated multidisciplinary approach and
significant patient commitment. The evidence base for cancer surveillance in this guideline are limited, emphasising the need
for prospective evaluation of the effectiveness of surveillance in the PHTS population.
Introduction
PTEN hamartoma tumour syndrome (PHTS), OMIM
158350, ORPHA:306498, is caused by germline variants
that affect function of the PTEN (phosphatase and tensin
homologue) gene, henceforth called “pathogenic variants”
(PV). It is a diverse multi-system disorder that encompasses
Cowden syndrome, Bannayan–Riley–Ruvalcaba syndrome
and Proteus-like syndrome, individuals with PHTS are at
increased risk of breast, thyroid, renal cancer, and possibly
endometrial cancer, colorectal cancer and melanoma [1].
The projected estimated lifetime risks of cancer in indi-
viduals with PHTS range from 85 to 89% for any cancer, 67
to 85% for female breast cancer, 6 to 38% for thyroid
cancer, 2 to 28% for endometrial cancer, 2 to 34% for renal
cancer, 9 to 20% for colorectal cancer and 0 to 6% for
melanoma [2–6]. These estimates and those given in
Table 1 are likely to be at the upper end of the true range
because of likely ascertainment bias in studies published to
date. Moreover these estimates are projections based on
small datasets and have wide confidence intervals. Ulti-
mately, larger prospective longitudinal studies, including
those individuals diagnosed in childhood because of
developmental problems, and asymptomatic relatives with
PTEN PVs, will be needed to define the risk more
accurately.
PHTS is rare and its clinical diagnosis relies on char-
acteristic signs and symptoms with variable expressivity,
followed by confirmatory genetic testing. Early identifica-
tion of affected individuals, which often precedes devel-
opment of advanced cancer by several years, allows
appropriate surveillance to be instituted, which is key to
timely detection of lesions. Genotype–phenotype analysis
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Acknowledgements.
* Marc Tischkowitz
mdt33@cam.ac.uk
1 Department of Medical Genetics, National Institute for Health
Research Cambridge Biomedical Research Centre, Cambridge
University Hospital NHS Foundation Trust, Cambridge, UK
2 Department of Genetics, Institut Curie, Paris Sciences et Lettres
Research University, Paris, France
3 Haaglanden Medical Center, The Hague, The Netherlands
4 Department of Human Genetics, Radboud University Medical
Center, Nijmegen, The Netherlands
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
has not been conclusive. A single study by Tan et al. found
a correlation between promoter PVs and breast cancer and
between nonsense PVs and colorectal cancer, this remains
unconfirmed [6]. There are thus currently no specific PVs
established that help to stratify patients for surveillance.
Diagnostic criteria for PHTS have been published and
are regularly updated by the National Comprehensive
Cancer Network® (National Comprehensive Cancer Net-
work® [NCCN®], 2019). They are divided into major and
minor criteria, and various combinations can be used to
reach a diagnosis. The availability of these criteria aids
clinicians in achieving consistency in clinical case defini-
tion. Conversely, gene-specific criteria for the interpretation
of PTEN variants have been developed by the ClinGen
PTEN Expert Panel [7]. They offer a more bespoke
approach to the American College of Medical Genetics
variant interpretation guidelines and are a helpful tool for
those involved in PTEN variant classification. In this light it
is important to keep in mind that historic reports did not
interpret variants with the same stringency as is now
applied.
Individuals with PHTS are at risk of several different
cancers which are amenable to early detection, but sur-
veillance protocols are complex, and there are no data
available documenting a consequent reduction in mor-
bidity and mortality, nor evaluating how well surveillance
is coordinated across countries. Moreover, there is no
international consensus on cancer surveillance in PHTS
and all current guidelines are based on expert opinion.
Guidelines have been published by the National Com-
prehensive Cancer Network® (NCCN®), and in the United
Kingdom guidelines have been developed for use in the
National Health Service by the UK Cancer Genetics
Group. Here we propose guidelines for member states of
the European Union which could also be used by other
countries.
Scope of the guidelines
This guideline is intended to address cancer surveillance of
individuals with PHTS and has been elaborated by members
of the European Reference Network (ERN) for Genetic
Tumour Risk Syndromes (GENTURIS). It aims specifically
to integrate available information to assist healthcare pro-
fessionals in evidence-based surveillance of individuals
with a confirmed germline pathogenic variant in PTEN. It
addresses surveillance for increased risk of cancer tailored
to tumour site, offers guidance on the imaging modality that
should be used for surveillance, on the age at which to start
surveillance for each cancer, and on frequency of sub-
sequent surveillance. The scope of this guideline was set to
determine what is currently known about the efficacy, fre-
quency and potential methods for surveillance, for breast,
thyroid, renal, endometrial or colorectal cancers in PHTS.
For melanoma, the risk is not sufficiently established to
consider additional surveillance at present. There is clearly
an increased risk of cancers in PHTS and this guideline
seeks to clarify this risk, and to suggest an approach to
screening that pragmatically balances the risk of harm from
the over-diagnosis of cancer with the potential benefits of
early identification of cancers, based on current incomplete
evidence.
Methods
ERN Guidelines on Cancer Surveillance Guideline for
Individuals PHTS consists of clinicians with expertise from
clinical genetics, gynaecology, endocrinology, dermatol-
ogy, radiology, gastroenterology, general surgery and
affected individuals and their representatives. The Guideline
Development Group was led by a Core Writing Group of
ERN GENTURIS HCP Members from different Member
Table 1 Estimates for projected
lifetime risks of tumours in
individuals with PHTS.
Cancer Current risk estimates Publications
Breast Cancer—lifetime up to 85%
Median age at diagnosis 38–46 years
81% [2], 85% [6], 77% [5]
Thyroid Cancer—lifetime 35%
Median age at diagnosis 37 years
Up to 75% risk of multinodular goitre,
adenomatous nodules and follicular adenomas
21% [2], 35% [6], 38% [5]
Endometrial Cancer—lifetime up to 28%
Risk starts late 30 s–early 40 s
19% [2], 28% [6], 2% [5]
Renal >Cancer—lifetime up to 34% (mostly papillary)
Risk starts late 40 s
15% [2], 34% [6], 2% [5]
Colorectal Cancer—lifetime up to 16%; Risk starts late 30 s
More than 90% have polyps, which may be
symptomatic
16% [2], 9%, [6] 3% [5],
13% [7]
Skin and vascular system Melanoma—~5%
Many non-malignant lesions
6% [6]
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States and who are recognised experts in specialised clinical
practice in the diagnosis and management of PHTS. The
Core Writing Group leads had joint meetings with a Patient
Advisory Group composed of affected individuals and
parent representatives that have experience with PHTS
syndrome.
The elaboration of these guidelines then additionally
involved external experts from different speciality areas
relevant to the scope of the guideline.
The guidelines were developed on the basis of 131
published articles extracted from Pubmed, using the fol-
lowing terms: (screening [title/abstract] OR surveillance
[title/abstract]) AND (PTEN [title] OR Cowden [Title])
AND “humans” [MeSH Terms].
Additional papers were requested from experts in the
field and references of all the papers were considered.
Papers were included if they contained any data on
screening or surveillance and renal cell, thyroid, endo-
metrial, breast or colorectal cancer in PHTS.
As is typical for many rare diseases, the volume of peer-
reviewed evidence available to consider for these guidelines
was small and came from a limited number of articles,
which typically reported on small samples or series. To
balance the weight of both published evidence and quantify
the wealth of expert experience and knowledge, we have
used for evidence grading the following scale: (i) strong
evidence: consistent evidence and new evidence unlikely to
change recommendation and expert consensus; (ii) moder-
ate evidence: expert consensus or majority decision but with
inconsistent evidence or significant new evidence expected
and (iii) weak evidence: inconsistent evidence AND limited
expert agreement.
Recommendations
The agreed recommendations are summarised in Table 2.
Breast
There is strong evidence of an increased risk of breast
cancer in women with germline PVs in PTEN [3, 5, 6].
However, there was weak evidence to address the question
of which modality should be used for surveillance and how
surveillance impacts on morbidity and mortality in PHTS.
Published studies to date suggest that the breast cancer risk
in PHTS is similar to that in women with germline PVs in
BRCA1/BRCA2. Therefore, many of the recommendations
are derived from the much larger evidence base which exists
for those hereditary breast cancer predisposition syndromes.
For those centres that wish to use mammography there is no
evidence of additional incremental benefit in performing
mammography more frequently than every 2 years with
surveillance in the intervening years being better performed
by magnetic resonance imaging (MRI).
Breast
No Recommendations Grading
1 Women should be screened for breast cancer Strong
2 Surveillance for breast cancer in PHTS
should use MRI (MRI should be ideally
conducted between day 5 and day 12 of the
menstrual cycle)
Strong
3 Surveillance for breast cancer with MRI
should probably start at 30
Strong
4 Women should be screened for breast cancer
annually
Strong
5. If surveillance for breast cancer in PHTS
additionally includes mammography this
should be undertaken no more frequently
than every 2 years
Moderate
Table 2 Guideline summary:
cancer surveillance protocol for
individuals with PTEN
hamartoma tumour syndrome.
Surveillance Interval From age Evidence
Breast cancer MRI Yearly 30 Strong
Mammography Every 2 years 40 Moderate
Risk-reducing surgery offered – – Moderate
Thyroid cancer Ultrasound Yearly 18a Strong
Renal cancer Ultrasound Every 2 years 40 Moderate
Colorectal cancer Baseline colonoscopyb – 35–40 Moderate
Melanoma Baseline skin examinationc – 30 Weak
Endometrial cancer Not recommendedd – – Weak
aModerate evidence for age of commencement of surveillance.
bConsider further surveillance as required by the gastroenterologist.
cConsider further surveillance as required by the dermatologist.
dConsider surveillance as part of clinical trial.
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Table (continued)
Breast
No Recommendations Grading
6 If surveillance for breast cancer with mam-
mography is offered this should probably
start at 40
Moderate
7 Risk reduction surgery should be offered
using the same considerations as for women
with germline BRCA1/BRCA2 pathogenic
variants
Moderate
Thyroid
There is strong evidence of an increased risk of thyroid
carcinoma in PHTS with evidence that this can arise at
relatively young ages [2, 3, 5, 6, 8, 9]. However, no study to
date has investigated which modality should be used for
surveillance or how surveillance impacts on morbidity and
mortality in PHTS. Although there are occasional reported
cases of children with PHTS developing thyroid carcinoma
[8, 9] the evidence is weak and does not support this being
frequent enough to justify the significant additional burden
that would be required to screen all individuals throughout
childhood. There is strong evidence that identification of
early stage thyroid carcinomas in other populations leads to
better outcomes [2] and that ultrasound is an appropriate
modality for surveillance for thyroid carcinomas.
Thyroid
No Recommendations Grading
1 Individuals should be offered surveillance
for thyroid cancer
Strong
2 Surveillance for thyroid cancer in PHTS
should be by US
Strong
3 Surveillance for thyroid cancer should
probably start at 18 years
Moderate
4 Individuals should probably be offered
surveillance for thyroid cancer annually
Moderate
Kidney
There is strong evidence of an increased risk of renal cell
carcinoma (RCC) in individuals with PHTS. However, no
study to date has investigated which modality should be
used for surveillance and how surveillance impacts on
morbidity and mortality in PHTS. One study of 219 indi-
viduals with PHTS identified nine individuals with
prevalent or incident history of RCC [10]. Histopathological
review of eight of these revealed complex tumours with
mixed cell types including papillary and chromophobe.
There is strong evidence that identification of early stage
RCCs in other populations leads to significantly better
outcomes [11]. There is strong evidence, in other popula-
tions that ultrasound is an appropriate modality for sur-
veillance for RCCs [12, 13]. It is possible that
ultrasonography will miss more aggressive tumours seen in
some predisposition syndromes such as Hereditary leio-
myomatosis and renal cell cancer where surveillance with
renal MRI is advocated [14], but at present there are
insufficient data to recommend renal MRI in PHTS.
Kidney
No Recommendations Grading
1 Individuals should be offered surveillance
for renal cell carcinoma (RCC).
Moderate
2 Surveillance for RCC in PHTS should be by
ultrasound
Moderate
3 Surveillance for RCC should probably
start at 40.
Moderate
4 Surveillance for RCC should probably be at
least every 2 years.
Moderate
Colon
Polyps are common in PHTS, and these are typically
hamartomas, although other types can also occur [15, 16]
There is weak evidence regarding colorectal cancer risk
in PHTS with some studies observing a modest increased
risk estimated to be 9–16% [3, 6, 15, 16], but this is not
a consistent finding [5]. In the studies that showed
an association the mean age at diagnosis of colorectal
cancer varied from 44 to 58 years. Therefore, the recom-
mendations for surveillance are broadly those that apply
to the general population, with the addition of a baseline
colonoscopy undertaken at 35–40 to assess polyp load.
Further surveillance would be determined by the findings
at baseline colonoscopy; if this was normal (no polyps)
then general population screening guidelines should be
followed.
Colon
No Recommendations Grading
1 Baseline colonoscopy should be undertaken
at 35–40 years to assess polyp load.
Moderate
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Table (continued)
Colon
No Recommendations Grading
2 If the baseline colonoscopy is normal,
individuals probably should not be screened
for colorectal cancer at any greater frequency
or earlier age than the general population.
Moderate
Skin
There is weak evidence regarding skin cancer risk in
PHTS. Therefore, the recommendations for surveillance
should be those that apply to the general population, with
the addition of a baseline skin examination at 30 by a
dermatologist who can determine whether further surveil-
lance is required and whether this should be done by a
specialist or generalist.
Skin
No Recommendations Grading
1 Individuals probably should have a baseline
skin examination at age 30, further surveil-
lance as required (consider every 2 years).
Weak
Endometrial
There is weak evidence regarding endometrial cancer
risk in PHTS. The limited evidence suggests that if these
cancers occur, they behave similarly to endometrial
cancers in other cancer syndromes. If surveillance for
endometrial cancer is offered it should be as part of a
clinical trial. Women should be advised to report red
flag symptoms (e.g. post menopausal or irregular
vaginal bleeding) without delay so they are promptly
investigated.
Endometrial
No Recommendations Grading
1 Women should probably not be screened for
endometrial cancer.
Moderate
2a If surveillance for endometrial cancer is
offered it should be as part of a clinical trial.
Strong
3a If surveillance for endometrial cancer is
offered, it should probably start at 40.
Weak
Table (continued)
Endometrial
No Recommendations Grading
4a If surveillance for endometrial cancer is
offered, it should probably be done at least
annually.
Weak
5 There is no clinical indication for endome-
trial cancer risk reduction surgery
(hysterectomy).
Weak
aNB: Recommendations 2–5, should be undertaken as part of a
clinical trial.
Discussion
The goal of cancer surveillance is to detect cancer at an
earlier stage than symptomatic presentation, when interven-
tions have a better chance of being curative. The proposed
surveillance recommendations for PHTS require a coordi-
nated multidisciplinary approach and significant patient
commitment. It is also important to remember that indivi-
duals with PHTS are at risk of multiple cancers over their
lifetime and surveillance for second cancers should not be
overlooked. As this is a very rare condition there is unlikely
to be a large health economic burden for the health service if
these guidelines are implemented. However, surveillance in
each individual is complex and additional resources may
need to be put in place for those health service providers that
are planning to offer surveillance at a local and regional level.
For this reason, we recommend that individuals who are at
50% risk of a PTEN PV initially proceed with genetic testing
to determine whether or not they require surveillance. For
individuals that meet the diagnostic criteria for PHTS, but
where no PV has been identified, surveillance should be
tailored on a case by case base, taking into account the
personal and family history of cancer. PHTS-related cancers
are predominately adult onset and no specific recommenda-
tions have been made for non-malignant manifestations in
adults or for the paediatric PHTS population whose man-
agement has been addressed elsewhere [17].
The evidence base for cancer surveillance in this guide-
line are limited. The quality of the evidence regarding
baseline risk has been rated as weak as it is non-randomised
and based on small numbers. A better understanding of the
age-related penetrance and the extent of the risk increase of
cancer is critical to improve risk counselling and risk-based
recommendations for cancer prevention and treatment. We
therefore recommend that national and international regis-
tries are established to collect prospective data on PHTS
individuals undergoing surveillance.
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Research should focus on understanding factors affecting
the risk of each type of cancer and translate this into more
accurate and personalised cancer risk estimates. There are
no data regarding preventative drugs (e.g. tamoxifen for
breast cancer, aspirin for bowel polyps/cancer) in PHTS.
Furthermore, research is needed to gain insights into the
cancer treatment and prognosis of PHTS patients. At pre-
sent cancer treatment of PHTS patients is similar to that for
sporadic cancers. Understanding the relation between
patient, tumour and treatment characteristics would be the
first step towards developing a tailored treatment for PHTS
patients. As PHTS is a rare disease, collaboration supported
by a common/central PHTS registry infrastructure is
essential to underpin this. In addition, the role of prophy-
lactic surgery has not been evaluated for this syndrome and
requires further research.
Patient education is a critical component of effective cancer
surveillance. This relates to both prevention (healthy living and
avoidance of cancer-causing behaviours) and early detection
(awareness of red flay symptoms for the key cancers). Patient
information groups can assist greatly with these aspects and are
a powerful resource for individuals with PHTS.
Early detection and surveillance of hereditary cancers
relies on established imaging methods such as ultra-
sonography and MRI. It is imperative that new surveillance
techniques are developed, that are not only more specific in
their detection ability, but also more easily available and
affordable for the healthcare systems. Utilisation of non-
invasive “liquid biopsy” technologies able to identify the
presence of genetic material from cancer cells in the blood
or molecular markers in urine or saliva that can identify
precursor lesions or cancer at its earliest stages are still
being evaluated in a research setting and individuals with
PHTS would be a good target population to trial these.
Another area of need is the identification and validation of
biomarkers that may distinguish aggressive, life-threatening
cancers from more indolent types. Above all, it will be
important to prospectively evaluate the effectiveness of
surveillance in the PHTS population and to foster global
collaborations with data sharing to enhance clinical care
and research opportunities for this group of high-risk
individuals.
Website
The complete guidelines can be downloaded from the ERN
website: https://www.genturis.eu.
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